FOLH1 and prostate carcinoma: In the last few years, improvements in molecular imaging and biomarker development have profoundly changed the field of prostate cancer diagnostics.6Prostate-specific membrane antigen (PSMA) positron emission tomography (PET)/computed tomography (CT) imaging and prostate-specific antigen (PSA) are those improvements, which became essential tools for comprehensive evaluation and personalized management.7, 8